Lewis lung carcinoma

From Wikipedia, the free encyclopedia
Jump to: navigation, search

Lewis lung carcinoma is a tumor discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass.[1] It is also called 3LL and LLC and is used as a transplantable malignancy. It has been used in many studies.[2]

In 1975, Munson discovered that cannabinoids suppress Lewis lung carcinoma cell growth. The mechanism of this action was shown to be inhibition of DNA synthesis[3] Cannabinoids increase the life span of mice carrying Lewis lung tumors and decrease primary tumor size.[4] There are multiple modes of action.[5]


  1. ^ Cancer Chemother Rep 2 1972 Nov;(3)1:325
  2. ^ Teicher, Beverly A.; Andrews, Paul A. (2004). Anticancer drug development guide: preclinical screening, clinical trials, and approval. Humana Press. pp. 197–. ISBN 978-1-58829-228-5. Retrieved 31 July 2011. 
  3. ^ Friedman MA (1977). "In vivo effects of cannabinoids on macromolecular biosynthesis in Lewis lung carcinomas.". Cancer Biochem Biophys. 2 (2): 51–4. PMID 616322. 
  4. ^ Kogan NM (2005). "Cannabinoids and cancer.". Mini Rev Med Chem. 5 (10): 941–52. PMID 16250836. doi:10.2174/138955705774329555. 
  5. ^ Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003). "Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis.". FASEB J. 17 (12): 1771–3. PMID 12958205. doi:10.1096/fj.02-1129fje.